How will you approach tapering of therapy in a patient with PsA who has responded well to tirzepatide and ixekizumab and has maintained disease remission for several years?

This is a difficult question to answer based on current data. While tapering is a standard strategy for DMARD therapies in many rheumatic diseases, many studies show that successful tapering or therapy discontinuation is not possible for most patients. If we are evaluating ixekizumab alone, few pati...

This is a good question.

If their weight is stable and they want to try to cut back on the tirzepatide, and they’ve already established good lifestyle habits such as exercise and healthy eating, then maybe that is a good one to taper and see how they do on a lower dose, or see how well they do if the...